At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 06-26 16:00:00 EDT
0.7155
-0.0135
-1.85%
盘后0.7100
-0.0055-0.77%
19:24 EDT
High0.7500Low0.6997Vol304.02K
Open0.7285D1 Closing0.7290Amplitude6.90%
Mkt Cap22.61MTradable Cap19.50MTotal Shares31.60M
T/O217.95KT/O Rate1.12%Tradable Shares27.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron says new Phase 2a analysis of laromestrocel in mild Alzheimer’s accepted for AAIC 2026 poster presentation
Reuters  ·  06-18
Longeveron says new Phase 2a analysis of laromestrocel in mild Alzheimer’s accepted for AAIC 2026 poster presentation
Longeveron wins EMA small, medium-sized enterprise status
Reuters  ·  06-09
Longeveron wins EMA small, medium-sized enterprise status
Longeveron Granted Small or Medium-Sized Enterprise (SME) Status by the European Medicines Agency (Ema)
THOMSON REUTERS  ·  06-09
Longeveron Granted Small or Medium-Sized Enterprise (SME) Status by the European Medicines Agency (Ema)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
GlobeNewswire  ·  06-09
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron Announces CFO Transition to Internal Successor
TIPRANKS  ·  06-06
Longeveron Announces CFO Transition to Internal Successor
BRIEF-Longeveron - On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing
Reuters  ·  06-06
BRIEF-Longeveron - On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing
Longeveron - on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing
THOMSON REUTERS  ·  06-06
Longeveron - on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing
Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing
THOMSON REUTERS  ·  06-06
Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing
Longeveron to present at BIO International Convention 2026
Reuters  ·  06-04
Longeveron to present at BIO International Convention 2026
Longeveron shifts to capital-light model, targets licensing partners for laromestrocel
Reuters  ·  05-21
Longeveron shifts to capital-light model, targets licensing partners for laromestrocel
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
THOMSON REUTERS  ·  05-21
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Benzinga  ·  05-14
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Longeveron Q1 revenue rises, beats analyst estimates
Reuters  ·  05-14
Longeveron Q1 revenue rises, beats analyst estimates
BRIEF-Longeveron Q1 EPS USD -0.19
Reuters  ·  05-14
BRIEF-Longeveron Q1 EPS USD -0.19
Longeveron Q1 Revenue USD 378 Thousand
THOMSON REUTERS  ·  05-14
Longeveron Q1 Revenue USD 378 Thousand
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
GlobeNewswire  ·  05-14
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000
Reuters  ·  05-14
Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000
Longeveron reports DMC approval for laromestrocel study to continue as designed
TIPRANKS  ·  05-12
Longeveron reports DMC approval for laromestrocel study to continue as designed
Longeveron Cut to Hold From Buy by Maxim Group
Dow Jones  ·  05-12
Longeveron Cut to Hold From Buy by Maxim Group
Longeveron downgraded to Hold from Buy at Maxim
TIPRANKS  ·  05-11
Longeveron downgraded to Hold from Buy at Maxim

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--